Business Context and Reporting Period
This Form 8-K is filed by Immudyne, Inc. (not Lifemd, Inc.) for the reporting period ending May 31, 2018. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and the resignation of an existing director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel changes rather than financial performance.
Material Changes
- Board Appointment: Stefan Galluppi, the Company's Chief Technology and Operations Officer, was appointed to the Board of Directors effective May 31, 2018.
- Board Resignation: Ryan Aldridge voluntarily resigned from the Board and all other positions effective May 31, 2018. The resignation was not due to any disagreement with the Company.
- Advisory Role: Mr. Aldridge agreed to serve as an unpaid advisor to the Company following his resignation.
Management Commentary, Risks, and Unusual Items
Compensatory Arrangements and Related Party Transactions:
- Mr. Galluppi receives $6,000 per month in cash compensation from the Company pursuant to a verbal agreement.
- The Company has a Services Agreement with American Nutra Tech, an entity wholly owned by Mr. Galluppi. Under this agreement, the Company issued 1,000,000 restricted shares of common stock.
- Rescission Right: The issuance of these shares was contingent on Immudyne PR distributing at least $500,000 to the Company by December 31, 2016. As this distribution did not occur, the Company retains a rescission right regarding these shares.
Risks: The filing notes no family relationships between Mr. Galluppi and other officers/directors and states there are no other applicable related party transactions beyond those disclosed.
Investor Verification Checklist
- Verify the current status of the 1,000,000 restricted shares issued to American Nutra Tech and whether the rescission right has been exercised.
- Confirm the terms of the verbal compensation agreement with Mr. Galluppi ($6,000/month) and its impact on future cash flow.
- Review the Company's financial statements to assess the impact of the failed $500,000 distribution target by Immudyne PR.
- Check subsequent filings to confirm if Mr. Aldridge's advisory role has resulted in any new contractual obligations.